Clinical trial · Observational
People-Powered Medicine (PPM): Rheumatoid Arthritis Non-responders to Biologic Therapies (RANT)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators are interested in enrolling patients with rheumatoid arthritis (RA) who had a difficult time getting their disease under control even after trying multiple RA therapies. The investigators believe that there may be common patterns in the genes of this group of RA patients compared to those with more "textbook RA." Understanding genetic factors can help doctors to know in advance who may not respond to conventional therapies and start with treatments that work. Learning about underlying genes that influence treatment may help the investigators to identify new targets for therapy, to ultimately improve the lives of patients with RA and inflammatory arthritis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rheumatoid Arthritis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Whole genome sequencing
- timeFrame
- Through study completion, averaging 1 year
- description
- Genomic data will be applied in an established bioinformatics pipeline to screen for uncommon variants and test association with exceptional treatment non-responders compared with TNFi responders.
Secondary outcomes (1)
- measure
- Subgroup analyses of treatment non-responders
- timeFrame
- 1 year
- description
- Patients who eventually find a therapy that controls their RA. The investigators will use prospective questionnaire data to subgroup patients into those who eventually find a treatment that works vs those who do not.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 95 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years * RA diagnosed by a rheumatologist * Poor control of RA disease activity with tumor necrosis factor inhibitor (TNFi) and another biologic therapy or small molecule approved for RA Exclusion Criteria: * If the reason for failed TNFi therapy was due to a contraindication or adverse reaction * Unable to provide blood sample
References
Publications (1)
- DERIVEDMcDermott GC, Jeffway M, Seyok T, Zhang H, Myasoedova E, Davis JM 3rd, Giles J, Coblyn J, Helfgott S, Massarotti E, Sands R, Weinblatt ME, Johansson T, Schmajuk G, Michaud K, Perry C, Churchill S, Liao KP. Rationale and design of the rheumatoid arthritis non-responders to treatment (RANT) study: Use of a bioinformatics platform and "decentralized" clinical recruitment design. Contemp Clin Trials. 2025 Sep;156:108000. doi: 10.1016/j.cct.2025.108000. Epub 2025 Jul 14. PMID 40669748